Although there is a great deal of research in the area of small molecules, genetic, and biologic therapies targeting factors involved in the pathophysiology of AD (amyloid β (Aβ), tau protein, or innate immune activation states) in the hope of finding disease-modifying treatments, there are still many open questions, and the burden on patients and families has not yet been overcome [26]. The gene discussed is MAPT; the disease is Alzheimer disease.